Ticagrelor is an antithrombotic antiplatelet drug that acts by direct and reversible competitive inhibition of the adensoine purinoceptor P2Y12 receptor. It has clinical benefits in people affected with acute coronary syndrome. It might also play a beneficial role on endothelial function. Ticagrelor can prevent the uptake of adenosine by human erythrocytes and can promote the liberation of adenosine triphosphate (ATP) from human erythrocytes.
General description
Ticagrelor (AZD6140) is a cyclopentyl-triazolopyrimidine.